UK-US Free Trade Deal Plans Disappoint Industry
UK Government Again Denies Claims That Drug Prices Will Rise
The UK has published its negotiating mandate for talks on a free trade deal with the US. As expected, intellectual property protection figures prominently, but the life sciences industry sees little merit in the government’s approach. It also warns that the UK’s future relationship with the EU could lead to greater regulatory burdens and costs.
You may also be interested in...
Despite the life sciences industry’s call for continued alignment of medicines regulation with the EU from next year and for some sort of co-operation with the European Medicines Agency, it seems the UK government is prepared to make only small concessions.
The UK’s decision to pull out of Europe’s Unified Patent Court system throws the future of the whole project into doubt.
Responding to UK government statements on the country’s future approach to trade deals with non-EU nations, the BGMA has insisted that there must be no changes to patent and exclusivity provisions that would block market entry for generic and biosimilar medicines.